Please login to the form below

Not currently logged in

Eisai in Chinese marketing deal with Orion

Eisai has entered into a comprehensive marketing agreement with Orion relating to Orion's breast cancer drug Fareston and its Parkinson’s disease treatment Eldepry

Japan-based pharmaceutical company Eisai has entered into a comprehensive marketing agreement with Finnish company Orion relating to Orion's breast cancer drug Fareston (toremifene citrate) and its Parkinson's disease treatment Eldepryl (selegiline hydrochloride).

Under the terms of the agreement, Eisai will acquire exclusive rights to market the two products in China, and will distribute them through its Chinese subsidiary Eisai China Inc. Both drugs were previously marketed in China by a local distributor, however, marketing rights were transferred to Eisai China following the expiration of the contract between the distributor and Orion in early June 2011.

Fareston is indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor positive or unknown tumours and is commonly used as an adjuvant therapy in postmenopausal breast cancer.

Eldepryl is used in combination with levodopa-containing agents to treat Parkinson's disease in patients who have previously had an inadequate response to treatment with levodopa therapies alone.

Eisai China will establish a new presence in China in the area of women's oncology by marketing Fareston and, with the addition of Eldepryl, will further enhance its portfolio of neurology products, which currently includes the anti-Alzheimer's agent Aricept (donepezil) and the peripheral neuropathy treatment Methycobal (mecobalamin). The company  seeks to make further contributions to address the diversified needs of and increase the benefits provided to breast cancer and Parkinson's disease patients in China.

13th July 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....